Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers A > Headlines for Amylin Pharmaceuticals Inc. > News item |
Amylin kept at outperform by Bear Stearns
Bear Stearns analyst Mark Schoenebaum maintained Amylin Pharmaceuticals, Inc. at outperform with a $51 price target on mixed Byetta prescriptions for the week ended Oct. 6. While total Byetta prescriptions are up 0.6% week over week, 5 mcg prescriptions are down 7.5% and 10 mcg prescriptions are up about 6.1%. Shares of the San Diego-based biopharmaceutical company were down 24 cents, or 0.51%, at $47.04. (Nasdaq: AMLN)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.